Cargando…

External applicability of SGLT2 inhibitor cardiovascular outcome trials to patients with type 2 diabetes and cardiovascular disease

BACKGROUND: Recent treatment guidelines support the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in patients with type 2 diabetes and cardiovascular disease based on the results of cardiovascular outcome trials (CVOTs). Applicability of these trials to everyday patients with type 2 diab...

Descripción completa

Detalles Bibliográficos
Autores principales:	Smidt, Lisanne C. A., Visseren, Frank L. J., de Ranitz-Greven, Wendela L., Nathoe, Hendrik M., Kappelle, L. Jaap, de Borst, Gert J., de Valk, Harold W., Westerink, Jan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8427950/ https://www.ncbi.nlm.nih.gov/pubmed/34496847 http://dx.doi.org/10.1186/s12933-021-01373-9

Ejemplares similares

The influence of baseline risk on the relation between HbA1c and risk for new cardiovascular events and mortality in patients with type 2 diabetes and symptomatic cardiovascular disease
por: Bots, Sophie H., et al.
Publicado: (2016)

Added value of cardiovascular calcifications for prediction of recurrent cardiovascular events and cardiovascular interventions in patients with established cardiovascular disease
por: van ’t Klooster, Cilie C., et al.
Publicado: (2021)

Thyroid-stimulating hormone levels in the normal range and incident type 2 diabetes mellitus
por: de Vries, T. I., et al.
Publicado: (2018)

Lifestyle changes and kidney function: A 10‐year follow‐up study in patients with manifest cardiovascular disease
por: Østergaard, Helena Bleken, et al.
Publicado: (2022)

The relation between urinary sodium and potassium excretion and risk of cardiovascular events and mortality in patients with cardiovascular disease
por: Groenland, Eline H., et al.
Publicado: (2022)

The long-term effect of mTOR inhibition on lipid and glucose metabolism in tuberous sclerosis complex: data from the Dutch TSC registry
por: Mulder, Femke V. M., et al.
Publicado: (2022)

Patients with Type 2 Diabetes Mellitus failing on oral agents and starting once daily insulin regimen; a small randomized study investigating effects of adding vildagliptin
por: de Ranitz-Greven, Wendela Lucia, et al.
Publicado: (2014)

Low-grade inflammation as a risk factor for cardiovascular events and all-cause mortality in patients with type 2 diabetes
por: Sharif, Shahnam, et al.
Publicado: (2021)

Multifocal cardiovascular calcification in patients with established cardiovascular disease; prevalence, risk factors, and relation with recurrent cardiovascular disease
por: van 't Klooster, Cilie C., et al.
Publicado: (2020)

End-stage kidney disease in patients with clinically manifest vascular disease; incidence and risk factors: results from the UCC-SMART cohort study
por: Østergaard, Helena Bleken, et al.
Publicado: (2021)

Screen-detected abnormal ankle brachial index: A risk indicator for future cardiovascular morbidity and mortality in patients with manifest cardiovascular disease
por: Jagt, Vivianne L., et al.
Publicado: (2022)

Arterial stiffness as a risk factor for cardiovascular events and all‐cause mortality in people with Type 2 diabetes
por: Sharif, S., et al.
Publicado: (2019)

Cohort profile: the Utrecht Cardiovascular Cohort–Second Manifestations of Arterial Disease (UCC-SMART) Study–an ongoing prospective cohort study of patients at high cardiovascular risk in the Netherlands
por: Castelijns, Maria C, et al.
Publicado: (2023)

Estimated Life Expectancy Without Recurrent Cardiovascular Events in Patients With Vascular Disease: The SMART‐REACH Model
por: Kaasenbrood, Lotte, et al.
Publicado: (2018)

Epilepsy, impaired functioning, and quality of life in patients with tuberous sclerosis complex
por: Vergeer, Menno, et al.
Publicado: (2019)

Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials
por: de Jong, Marit, et al.
Publicado: (2017)

Cardiovascular Diseases: Therapeutic Potential of SGLT-2 Inhibitors
por: Frąk, Weronika, et al.
Publicado: (2023)

Physical exercise volume, type, and intensity and risk of all-cause mortality and cardiovascular events in patients with cardiovascular disease: a mediation analysis
por: Bonekamp, Nadia E, et al.
Publicado: (2023)

Relationship between classic vascular risk factors and cumulative recurrent cardiovascular event burden in patients with clinically manifest vascular disease: results from the UCC-SMART prospective cohort study
por: de Vries, Tamar Irene, et al.
Publicado: (2021)

Cardiovascular and Renal Benefits of SGLT2 Inhibitors: A Narrative Review
por: Rabizadeh, Soghra, et al.
Publicado: (2019)

Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus
por: Suzuki, Yuta, et al.
Publicado: (2022)

Renal and Cardiovascular Metabolic Impact Caused by Ketogenesis of the SGLT2 Inhibitors
por: Vargas-Delgado, Ariana P., et al.
Publicado: (2023)

Systematic review and meta-analysis: SGLT2 inhibitors, blood pressure and cardiovascular outcomes
por: Benham, Jamie L., et al.
Publicado: (2021)

Mediation analysis of the relationship between type 2 diabetes and cardiovascular events and all‐cause mortality: Findings from the SMART cohort
por: Sharif, Shahnam, et al.
Publicado: (2019)

Cardiovascular risk and lifetime benefit from preventive treatment in type 2 diabetes: A post hoc analysis of the CAPTURE study
por: Østergaard, Helena Bleken, et al.
Publicado: (2022)

Rare oxygen, a rare way to diagnose Conn's syndrome
por: Greven, Wendela L., et al.
Publicado: (2008)

Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors: Benefits in Diabetics With Cardiovascular Disease
por: Aftab, Saba, et al.
Publicado: (2020)

Preventing major adverse cardiovascular events by SGLT-2 inhibition in patients with type 2 diabetes: the role of kidney
por: Giugliano, Dario, et al.
Publicado: (2020)

Multifactorial Prevention of Cardiovascular Disease in Patients with Hypertension: the Cardiovascular Polypill
por: Lafeber, M., et al.
Publicado: (2016)

Effects of treatment with SGLT-2 inhibitors on arginine-related cardiovascular and renal biomarkers
por: Gessner, Arne, et al.
Publicado: (2022)

Cardiovascular outcomes and safety of SGLT2 inhibitors in chronic kidney disease patients
por: Chen, Xiutian, et al.
Publicado: (2023)

Misinterpretation of ischaemic infarct location in relationship to the cerebrovascular territories
por: Hartkamp, Nolan S, et al.
Publicado: (2016)

Modifiable risk factors in adults with and without prior cardiovascular disease: findings from the Indonesian National Basic Health Research
por: Arsyad, Dian Sidik, et al.
Publicado: (2022)

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review
por: Kalra, Sanjay
Publicado: (2016)

Off-target Effects of Sodium-glucose Cotransporter 2 (SGLT-2) Inhibitor in Cardiovascular Disease
por: Hwang, Jiwon, et al.
Publicado: (2020)

The readiness of public primary health care (PUSKESMAS) for cardiovascular services in Makasar city, Indonesia
por: Arsyad, Dian Sidik, et al.
Publicado: (2022)

SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials
por: Inzucchi, Silvio E, et al.
Publicado: (2015)

SGLT2is vs. GLP1RAs Reduce Cardiovascular and All-Cause Mortality
por: Qiu, Mei, et al.
Publicado: (2021)

The cardiovascular effects of SGLT2 inhibitors, RAS inhibitors, and ARN inhibitors in heart failure
por: Ji, Peng‐juan, et al.
Publicado: (2023)

Clinical efficacy of SGLT2 inhibitors with different SGLT1/SGLT2 selectivity in cardiovascular outcomes among patients with and without heart failure: A systematic review and meta-analysis of randomized trials
por: Lee, Mei-Chuan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pdse8djfrrivcu5pikq7eto9r0